Please use the Contact Us form or ping us here on twitter to add value added information to this page. We greatly appreciate your inputs as it helps us sharpen our thinking (pros, cons, insights, and so forth) about the company and it also helps other readers. This is a social experiment for now. 


Roger Kotch Interview (underneath the Bigger Capital Research section located below)

Promis Neurosciences Adopts Shareholder Rights Plan (1/25/2016)

Promis NeuroSciences Deck (12/3/2015) 

White Paper Highlights the Importance of am Alzheimer's Patent Filing.



Quarterly Results & Company News – Nov. 12th, 2015 from ProMIS™ Neurosciences, Inc. on Vimeo.


Alzheimer's: Light at the End of the Tunnel (w/ Q&A) - ProMIS Neurosciences from ProMIS™ Neurosciences, Inc. on Vimeo.



 Bigger Capital Research:


Roger Kotch Interview

1. What is your background?

My background is in finance, previously a stock broker and real estate developer.

2. When did you get involved with Promis Neurosciences ($PMN.TO, Formerly Amorfix)? and why?

I got involved with Amorfix / Promis in 2005 when I had a public Company, Luxor Developments Ltd, which had recently sold its main asset and had no business, but cash in the bank. I was introduced to Neil Cashman the later part of that year and was immensely impressed by his vision and accolades. We merged the Company with his technology and renamed the Company Amorfix Life Sciences.

3. What were the company's initial goals?

The Companies initial goal was to develop a diagnostic for vCJD (Variant Jakob-Creuzfeldt Disease or commonly known as mad cow disease) and create a therapeutic for it. Along that pathway there was studies undertaken to identify misfolded prions for other diseases.

4. Can you give us a concise timeline of the history of the company?

Initially the Company was focused on a diagnostic for VCJD as over 30,000 tests conducted were all positive. Neil increased the sensitivity to 1to 5 million sensitivity. The Company was also working on sheep scrapie and cronic wasting disease, along with a diagnostic for AD and a therapeutic. ALS was also being looked at and SOD1 was being substantiated.

5. Can you tell us more about the involvement of Promis with the variant Jakob-Creuzfeldt disease (vCJD)?

The vCJD test was a success and over 30,000 tests supported Neils findings, however when you look at the possible liability to the U.K. Government, one must raise the question why they sent 2 samples for testing and those samples could not detect VCJD? Christine Lord has fought most of her journalistic career on under covering the scandal this deadly disease has created. The U.K. Government allowed the disease to be created by allowing rendered animal products to be fed to cattle, which was subsequently banned by all Governments after BSE was found to be prevalent in U.K. cattle.
There are about 700,000 British citizens infected with vCJD and it is a ticking time bomb when the disease will surface and an onslaught of victims will be subject to this horrific disease, which the U.K. Government knows fair well.
6. Why didn't it work? Was the science right?
The test did work and when you have your biggest market telling you they no longer want to explore a test, then you must stop spending money on a diagnostic that your number one customer refuses to acknowledge.
7. Then what? What happened with Ovarian cancer?
The ovarian cancer project is temporarily put on hold as the Company focuses on our diagnostics and therapeutics for AD. The last test results showed a significant reduction in tumor growth using Urease.
 8. Why was the company a failure for much of its history?
The Company has been plagued with poor management and myopic thinking by members of the board. The science has always been strong, but the management very weak.
9. Why do you think its science is right?
The science Neil Cashman has now is being endorsed by two major professors from two different universities, Dr. Marc Diamond and Dr. Larry Walker, who both identified strains in abeta amyloids that cause AD. These academics have validated Neil's work and progression, which further proves he is on the right track.
10. In its current form, what do you see the potential of Promis to be?
The potential for Promis is to identify all the strains for AD, patent them, develop monoclonal antibodies and partner the technology, or sell it outright.
11. Do you think investors are overlooking this company? If so, why?
Investors have undergone shareholder fatigue and are frustrated with previous managements performance and lack of business acumen. The science is strong and all that remains is to get a better way of exposing this to the media and U.S. investors.
12. What do you think about the current management?
I believe current management are very committed to seeing this Company become a success story and they have the pharmaceutical connections to do just that.
13. Do you think the company is correct in stating that 8 epitopes are involved in most Alzheimer's disease cases?
The Company along with the two other scientists further add credence to Neil's hypothesis about strains and how to stop the propagation of misfolded proteins.
14. Do you think the company will patent the remaining 7 epitopes it hasn't patented yet?
Yes the Company is in the process of patenting the remaining epitopes.
15. When do you think this will happen?
The epitopes are presently in for patent.
 16. Can you lay out the current IP of the company including the IPs that were shelved?
17. What could go wrong with your investment thesis?
The only thing at this point that could go wrong with this investment is that a Company tries to take us out at a cheap price, which I am sure the Directors are cognizant of.
18. What do you think about the scientific team (Cashman, Plotkin, and company)?
One just has to read the accolades Plotkin and Cashman have received to know that this team is world class and capable of creating a diagnostic and new therapies for AD and other neurological diseases.
19. How big do you think this company can become on a market cap basis?

The market cap question has always been one of difficulty, as one must look at the market of AD alone. Biogen had positive results released recently on their AD drug and their market cap jumped by 20 billion dollars in one day, subsequently they had not so favorable results and it dropped by 20 billion. One therapeutic to stop the progression of AD is obviously worth at least one billion and having 8 strains patented and being able to diagnose those strains is worth billions of dollars and if the markets know of this scientific news, we could see very high double digits on the stock.

I suggested to the board that when they are entertaining a takeover that the other scientific IPs we have be taken out and another Company formed to proceed with the cancer and ALS therapeutics.


Research (pros and cons):


  •  None. Please let us know if you find a piece worth linking to.


   Company Website:


  Social Media Stock Streams:


Quotes and Financial Information:




    National Institute of Health:


    Other Resources: 



 AMF/PMN Patent: Methods and compositions to treat and detect misfolded-  SOD1 mediated diseases:



American Academy of Neurology(AAN)-Breakthroughs in Neurology Orlando Jan 15-18 2016

AAN 2016 Annual Meeting Vancouver April 15-21 2016

Alzheimer's Association Annual Conference(AAIC)2016 Toronto July 22-28 2016